CSG’s Deepening Munitions Integration and Chemical Foray Fail to Quell Investor Unease

The Czechoslovak Group is betting big on two fronts — critical components for artillery and a stake in specialty chemicals — yet the market continues to punish its shares. On Friday, CSG stock slid another 2.55 percent to €15.26, dragging the seven-day loss to 15.5 percent. The decline comes despite a string of operational positives that would normally buoy a defense contractor.

At the heart of the sell-off lies a confidence gap. Reports from investigative platform Follow the Money have raised transparency questions around framework agreements with Slovakia’s defence ministry, while a Spanish subsidiary was temporarily excluded from NATO procurement due to alleged irregularities. CSG insists it has met all compliance requirements, but the reputational shadow has proven hard to shake.

A Two-Pronged Strategic Push

On June 3, CSG secured two large orders from European NATO members for mechanical and electronic fuzes used in large-calibre ammunition. The combined value sits in the high double-digit million euro range. To execute the contracts, the group is setting up a new joint venture in Slovakia called Fuchs Electronics Europe, partnering with South Africa’s Reunert. The facility, located at the ZVS site in Dubnica nad Váhom, will focus on the precision electronics that make modern fuzes capable of point detonation, delay, time, and airburst modes — a critical bottleneck in Europe’s ammunition supply chains.

Deliveries for the fuze orders are slated to begin later this year, reinforcing CSG’s push into higher-value components. The company already produces large-calibre ammunition at an annual capacity exceeding 800,000 rounds, and controlling fuze production strengthens vertical integration. The move also opens the door to supplying other European munitions makers.

Alongside the defence play, CSG has quietly built a significant position in the chemicals sector. Through its subsidiary Staluna Trade, the group now holds more than 20 percent of German specialty chemical manufacturer Alzchem — roughly half directly and half via financial instruments. The stake signals a deliberate diversification away from pure defence exposure, though investors have yet to reward the strategy.

Should investors sell immediately? Or is it worth buying CSG?

Operational Strength Meets Technical Weakness

The group’s first-quarter numbers tell a story of robust demand. Revenue rose 13.8 percent year-on-year to €1.544 billion, while operating EBIT reached €372 million. The defence systems segment — CSG’s core — generated €1.251 billion in sales, up 26.5 percent, with an operating margin of 28.4 percent. The order backlog at the end of March stood at €17 billion, with a further €27 billion in advanced negotiation.

Management’s full-year guidance remains unchanged: revenue in the range of €7.4 billion to €7.6 billion, an operating EBIT margin of roughly 24–25 percent, capital expenditure at about 8.5 percent of sales, and net debt kept below 1.3 times EBITDA.

Yet the stock is trading 57.7 percent below its all-time high of €36.05, hit shortly after the January IPO at €25 per share. The relative strength index (RSI) sits at 32.8 — technically oversold — while the 50-day moving average of €19.92 is a full 21.4 percent above the current price. The 30-day annualised volatility of 78.45 percent underscores the wild swings that have kept many buyers on the sidelines.

What Comes Next

The divergence between operational momentum and market sentiment has left analysts divided. Some argue that the recent weakness is a temporary crisis of confidence, likely to fade as deliveries ramp up. Others point to lingering governance questions and the sheer scale of the stock’s post-IPO decline as signs of deeper structural issues.

For now, the next major catalyst is the quarterly report due in August. It will test whether the record order book can translate into accelerating profit growth — and whether CSG’s twin bets on fuzes and chemicals can finally overcome the weight of investor unease.